Generics companies Mylan (Nasdaq: MYL) and Teva Pharmaceutical Industries (NYSE: TEVA) have shown their commitment to fighting the COVID-19 pandemic by making announcements around hydroxychloroquine sulfate tablets, which they both manufacture.
Mylan has restarted production of the tablets at its West Virginia manufacturing facility in the USA, in order to meet the potential for increased demand resulting from potential effectiveness of the product in treating cases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze